Optiver Holding
LGND icon

Optiver Holding’s Ligand Pharmaceuticals LGND Stock Holding History

Optiver Holding’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-84
Closed -$14.9K – 2753
2025
Q3 		$14.9K Buy
+84
New +$12.5K ﹤0.01% 1077

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Optiver Holding's LGND Position: Q4 2025 in Review

Optiver Holding sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 84 shares — an estimated $14.9K sold.

Optiver Holding first reported a position in LGND in Q3 2025 and held it in 1 quarter. The position peaked at $14.9K in Q3 2025. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Optiver Holding reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Optiver Holding sold 84 Ligand Pharmaceuticals shares in Q4 2025, an estimated $14.9K.
  • Optiver Holding first reported a position in Ligand Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Optiver Holding's Ligand Pharmaceuticals position peaked at $14.9K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Optiver Holding's 13F filing for Q4 2025, filed 17 Feb 2026.